Athira Pharma downgraded by Jefferies with a new price target
$ATHA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Jefferies downgraded Athira Pharma from Buy to Hold and set a new price target of $3.00 from $32.00 previously